Issues
-
Cover Image
Cover Image
On the Cover
Perfusion defects in TNF-nanoparticle and heat treated tumors. Tumor perfusion in the SCK murine mammary carcinoma, hind limb model, after treatment with TNF-conjugated gold nanoparticles and/or hyperthermia, was non-invasively imaged using contrast enhanced ultrasonography. Perfused vasculature is indicated by orange-red color. Marked defects in tumor perfusion persisted in tumors receiving combined treatment. The nanoparticle (PT-cAu-TNF) is 33nm pegylated, colloidal gold coated with TNF. For details, see Visaria et al. in this issue. - PDF Icon PDF LinkTable of Contents
Drug Development Series: Review
Review
Research Articles: Targets
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel
Research Articles: Therapeutics
Efficacy of a nitric oxide–releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts
Curcumin induces caspase-3-dependent apoptotic pathway but inhibits DNA fragmentation factor 40/caspase-activated DNase endonuclease in human Jurkat cells
Construction of a novel DNA decoy that inhibits the oncogenic β-catenin/T-cell factor pathway
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
Aerosol delivery of urocanic acid–modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice
Research Articles: Development
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.